Bristol Myers Squibb Company $BMY Shares Sold by Quilter Plc

Quilter Plc reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 44.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,677 shares of the biopharmaceutical company’s stock after selling 32,856 shares during the period. Quilter Plc’s holdings in Bristol Myers Squibb were worth $1,880,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. MBM Wealth Consultants LLC acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $569,000. Sector Gamma AS boosted its position in Bristol Myers Squibb by 43.2% during the third quarter. Sector Gamma AS now owns 581,267 shares of the biopharmaceutical company’s stock worth $26,215,000 after purchasing an additional 175,267 shares in the last quarter. 1834 Investment Advisors Co. grew its holdings in Bristol Myers Squibb by 1.3% in the third quarter. 1834 Investment Advisors Co. now owns 159,572 shares of the biopharmaceutical company’s stock valued at $7,197,000 after purchasing an additional 2,075 shares during the last quarter. Sagespring Wealth Partners LLC increased its position in shares of Bristol Myers Squibb by 8.5% in the third quarter. Sagespring Wealth Partners LLC now owns 15,365 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 1,206 shares in the last quarter. Finally, Oxbow Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 3rd quarter worth $6,485,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on BMY. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. Citigroup reissued a “neutral” rating and set a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 7th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Finally, Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Price Performance

BMY stock opened at $54.61 on Friday. The stock has a market capitalization of $111.17 billion, a price-to-earnings ratio of 18.45, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The stock’s fifty day simple moving average is $52.57 and its 200-day simple moving average is $48.40.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter in the prior year, the company posted $1.80 EPS. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 85.14%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY struck a sizable collaboration and exclusive license deal with Janux Therapeutics (worth up to ~$800M), signaling near‑term external innovation that could bolster BMY’s oncology pipeline and near‑term partnering upside. Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
• Positive Sentiment: BMY and BioNTech advanced a Phase 3 lung‑cancer program for pumitamig, a potential new competitor to Keytruda — a successful readout would be material to oncology revenue upside. Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
• Positive Sentiment: BMY reported progress in a China mesothelioma trial for Opdivo + Yervoy, which signals additional oncology label/market expansion opportunities in a large market. Bristol Myers Squibb Advances Opdivo/Yervoy in China Mesothelioma Trial, Signaling New Oncology Upside
• Positive Sentiment: BMY announced a collaboration with Microsoft to develop AI‑driven early detection tools for lung cancer — a strategic move that could accelerate diagnostics-linked R&D and potential data/technology synergies. Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
• Positive Sentiment: Analysts at UBS turned more constructive on biotech/pharma, including BMY exposure, which supports investor sentiment around sector recovery and dividend stability. Bristol-Myers (BMY): UBS turns bullish as biotech and pharma show signs of a recovery
• Neutral Sentiment: Coverage pieces are re‑evaluating BMY’s valuation and pipeline after the Microsoft pact and Camzyos trial news — useful context but not an immediate earnings swing. A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results
• Neutral Sentiment: Analyst action: Citi placed BMY at a Hold, tempering upside expectations from some investors even as clinical headlines roll in. Bristol-Myers Squibb (BMY) Receives a Hold from Citi
• Negative Sentiment: An analyst lowered Q1 EPS estimates for BMY, adding short‑term earnings pressure and a reason for cautious positioning ahead of upcoming quarterly/clinical readouts. Q1 EPS Estimate for Bristol Myers Squibb Lowered by Analyst
• Neutral Sentiment: Stock commentary noting “mixed returns and pipeline developments” flags that while R&D catalysts are meaningful, execution risk and valuation remain focal for investors. Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.